Related Experiment Video

Updated: Sep 27, 2025

An Educational Video Demonstration of How to Prone a Critically Ill Intubated Patient
07:16

An Educational Video Demonstration of How to Prone a Critically Ill Intubated Patient

Published on: November 30, 2022

3.6K

ACEi/ ARB and Deaths of COVID-19 Patients

Gulam Navi Azad1, Anoop Kumar2

  • 1Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, Lucknow (U.P.), India.

Current Hypertension Reviews
|April 8, 2022
PubMed

Insights

This study found no link between angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (ACEi/ARB) and mortality in COVID-19 patients. Clinicians can continue prescribing these vital medications for hypertension management during the pandemic.

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Pharmacology

Background:

  • The use of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (ACEi/ARB) in hypertensive patients with COVID-19 remains a clinical uncertainty.
  • Understanding the association between ACEi/ARB use and COVID-19 patient mortality is crucial for guiding treatment strategies.

Approach:

  • A systematic literature search was performed in PubMed from December 2019 to October 2020.
  • Meta-analysis of 7 studies involving 1,566 subjects was conducted using RevMan 5 and a random-effect model.
  • The odds ratio was calculated to assess the relationship between ACEi/ARB use and mortality in COVID-19 patients.

Key Points:

  • The meta-analysis revealed an odds ratio of 0.86 [0.41, 1.81].
  • This indicates no statistically significant association between the use of ACEi/ARB and mortality rates in COVID-19 patients.
  • The findings suggest that current prescribing practices for ACEi/ARB in this population can be maintained.

Conclusions:

  • Current evidence does not support a link between ACEi/ARB use and increased mortality in COVID-19 patients.
  • Continued use of ACEi/ARB in hypertensive COVID-19 patients is recommended pending further research.
  • This study contributes to clarifying the safety profile of ACEi/ARB in the context of COVID-19 infection.

Keywords:
Angiotensin-converting enzyme inhibitor (ACEI)Angiotensin-receptor blocker (ARB)COVID-19Rev Man 5mortalityodd ratio

More Related Videos

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis03:40

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Published on: December 20, 2024

714
Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device09:36

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device

Published on: September 24, 2020

2.9K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
539
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
953
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
997
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
57
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
865
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
36